Investigational drug · Phase 3
PP405 0.05%
Also called: PP405
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Androgenetic Alopecia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
2 still active
All registered trials
3
Any phase or sponsor naming "PP405 0.05%"
First trial start
2024
Jun 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PP405 0.05%", any sponsor or status.
Conditions studied
As listed on its trial records.
- Androgenetic Alopecia
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "PP405 0.05%" as an intervention, largest first.
- Phase 2/3 Efficacy and Safety of PP405 in Adult MalesPivotal-lookingRecruiting
Pelage Pharmaceuticals, Inc.Industry
NCT07819435 · 600 participants (planned) · Start Sep 21, 2026 · Primary completion Dec 2027
Drug: PP405 0.05% Topical Gel; Vehicle Topical Gel · For: Androgenetic Alopecia
Sites: Birmingham, Alabama; Fort Smith, Arkansas; Hot Springs, Arkansas · 63 sites in all
- Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic AlopeciaPivotal-lookingRecruiting
Pelage Pharmaceuticals, Inc.Industry
NCT07907783 · 200 participants (planned) · Start Nov 10, 2026 · Primary completion Sep 2027
Drug: PP405 0.05% Topical Gel; Vehicle Topical Gel · For: Androgenetic Alopecia
Sites: Hot Springs, Arkansas; Atlanta, Georgia; New York, New York · 6 sites in all
Pelage Pharmaceuticals, Inc.Industry
NCT06393452 · 78 participants · Start Jun 5, 2024 · Primary completion Jul 16, 2025
Drug: PP405 0.05% Topical Gel; Topical Vehicle Gel · For: Androgenetic Alopecia
Sites: Encinitas, California; Thousand Oaks, California; Indianapolis, Indiana · 8 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging pharmacotherapies for androgenetic alopecia.
Agrawal A, Dreifus EM, Tosti A · Expert Opin Pharmacother 2026
Also in development for Androgenetic Alopecia
- VDPHL01Phase 34 trials
Veradermics, Inc. · Androgenetic Alopecia, AGA, Male Pattern Baldness
- DA-001Phase 31 trial
Applied Biology, Inc. · Telogen Effluvium, Female Pattern Hair Loss, Female Pattern Hair Loss, Androgenic Alopecia
- SecretomeConditioned, Umbilical Cord Mesenchymal Stem Cells derived ConditionedPhase 24 trials
PT. Prodia Stem Cell Indonesia · Acute Respiratory Distress Syndrome, Androgenetic Alopecia, Ischemic Stroke
- AD-3031Phase 21 trial
Moogene Medi Co., Ltd · Androgenetic Alopecia
- AD-303APhase 21 trial
Moogene Medi Co., Ltd · Androgenetic Alopecia
- EPI-001Phase 21 trial
Epibiotech · Androgenetic Alopecia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.